Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

SPARC is required for the maintenance of glucose homeostasis and insulin secretion in mice.

Atorrasagasti C, Onorato A, Gimeno ML, Andreone L, Garcia M, Malvicini M, Fiore E, Bayo J, Perone MJ, Mazzolini G.

Clin Sci (Lond). 2019 Jan 9. pii: CS20180714. doi: 10.1042/CS20180714. [Epub ahead of print]

PMID:
30626728
2.

Immunomodulatory Properties and Potential Therapeutic Benefits of Muse Cells Administration in Diabetes.

Perone MJ, Gimeno ML, Fuertes F.

Adv Exp Med Biol. 2018;1103:115-129. doi: 10.1007/978-4-431-56847-6_6.

PMID:
30484226
3.

Interactions Between the Neuroendocrine System and T Lymphocytes in Diabetes.

Andreone L, Gimeno ML, Perone MJ.

Front Endocrinol (Lausanne). 2018 May 17;9:229. doi: 10.3389/fendo.2018.00229. eCollection 2018. Review.

4.

Pluripotent nontumorigenic multilineage differentiating stress enduring cells (Muse cells): a seven-year retrospective.

Fisch SC, Gimeno ML, Phan JD, Simerman AA, Dumesic DA, Perone MJ, Chazenbalk GD.

Stem Cell Res Ther. 2017 Oct 18;8(1):227. doi: 10.1186/s13287-017-0674-3. Review.

5.

Pluripotent Nontumorigenic Adipose Tissue-Derived Muse Cells have Immunomodulatory Capacity Mediated by Transforming Growth Factor-β1.

Gimeno ML, Fuertes F, Barcala Tabarrozzi AE, Attorressi AI, Cucchiani R, Corrales L, Oliveira TC, Sogayar MC, Labriola L, Dewey RA, Perone MJ.

Stem Cells Transl Med. 2017 Jan;6(1):161-173. doi: 10.5966/sctm.2016-0014. Epub 2016 Aug 2.

6.

GR-independent down-modulation on GM-CSF bone marrow-derived dendritic cells by the selective glucocorticoid receptor modulator Compound A.

Barcala Tabarrozzi AE, Andreone L, Deckers J, Castro CN, Gimeno ML, Ariolfo L, Berguer PM, Antunica-Noguerol M, Liberman AC, Vettorazzi S, Tuckermann JP, De Bosscher K, Perone MJ.

Sci Rep. 2016 Nov 18;6:36646. doi: 10.1038/srep36646.

7.

Effect of TGF-β1 Stimulation on the Secretome of Human Adipose-Derived Mesenchymal Stromal Cells.

Rodríguez TM, Saldías A, Irigo M, Zamora JV, Perone MJ, Dewey RA.

Stem Cells Transl Med. 2015 Aug;4(8):894-8. doi: 10.5966/sctm.2015-0012. Epub 2015 May 29.

8.

A mystery unraveled: nontumorigenic pluripotent stem cells in human adult tissues.

Simerman AA, Perone MJ, Gimeno ML, Dumesic DA, Chazenbalk GD.

Expert Opin Biol Ther. 2014 Jul;14(7):917-29. doi: 10.1517/14712598.2014.900538. Epub 2014 Apr 19. Review.

9.

Curcumin ameliorates autoimmune diabetes. Evidence in accelerated murine models of type 1 diabetes.

Castro CN, Barcala Tabarrozzi AE, Winnewisser J, Gimeno ML, Antunica Noguerol M, Liberman AC, Paz DA, Dewey RA, Perone MJ.

Clin Exp Immunol. 2014 Jul;177(1):149-60. doi: 10.1111/cei.12322.

10.

Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas.

Curic S, Wu Y, Shan B, Schaaf C, Utpadel D, Lange M, Kuhlen D, Perone MJ, Arzt E, Stalla GK, Renner U.

J Neurooncol. 2013 Jul;113(3):385-96. doi: 10.1007/s11060-013-1148-9. Epub 2013 May 11.

PMID:
23666203
11.

[First South american network of biomedical research. Education and biotechnology for health].

Perone MJ, Velázquez G, Rojas de Arias A, Chamorro G, Coluchi N, Pirmez C, Savino W, Barbeito L, Arzt E.

Medicina (B Aires). 2013;73(1):75-7. Spanish.

12.

Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus.

Barcala Tabarrozzi AE, Castro CN, Dewey RA, Sogayar MC, Labriola L, Perone MJ.

Clin Exp Immunol. 2013 Feb;171(2):135-46. doi: 10.1111/cei.12019. Review.

13.

Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas.

Shan B, Schaaf C, Schmidt A, Lucia K, Buchfelder M, Losa M, Kuhlen D, Kreutzer J, Perone MJ, Arzt E, Stalla GK, Renner U.

J Endocrinol. 2012 Sep;214(3):389-98. Epub 2012 Jun 27.

PMID:
22739211
14.

Compound A, a dissociated glucocorticoid receptor modulator, inhibits T-bet (Th1) and induces GATA-3 (Th2) activity in immune cells.

Liberman AC, Antunica-Noguerol M, Ferraz-de-Paula V, Palermo-Neto J, Castro CN, Druker J, Holsboer F, Perone MJ, Gerlo S, De Bosscher K, Haegeman G, Arzt E.

PLoS One. 2012;7(4):e35155. doi: 10.1371/journal.pone.0035155. Epub 2012 Apr 9. Erratum in: PLoS One. 2012;7(5): doi/10.1371/annotation/12a8fc89-5f47-4bad-8863-863d99a0e52d.

15.

Novel medical therapies for pituitary tumors.

Theodoropoulou M, Labeur M, Paez Pereda M, Haedo M, Perone MJ, Renner U, Arzt E, Stalla GK.

Front Horm Res. 2010;38:158-64. doi: 10.1159/000318506. Epub 2010 Jul 5. Review.

PMID:
20616507
16.

Curcumin inhibits the growth, induces apoptosis and modulates the function of pituitary folliculostellate cells.

Schaaf C, Shan B, Onofri C, Stalla GK, Arzt E, Schilling T, Perone MJ, Renner U.

Neuroendocrinology. 2010;91(2):200-10. doi: 10.1159/000287236. Epub 2010 Feb 17.

PMID:
20160430
17.

Disease-modifying immunotherapy for the management of autoimmune diabetes.

Castro CN, Barcala Tabarrozi AE, Noguerol MA, Liberman AC, Dewey RA, Arzt E, Morelli AE, Perone MJ.

Neuroimmunomodulation. 2010;17(3):173-6. doi: 10.1159/000258716. Epub 2010 Feb 4. Review.

PMID:
20134195
18.

Curcumin acts as anti-tumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in vitro and in vivo.

Schaaf C, Shan B, Buchfelder M, Losa M, Kreutzer J, Rachinger W, Stalla GK, Schilling T, Arzt E, Perone MJ, Renner U.

Endocr Relat Cancer. 2009 Dec;16(4):1339-50. doi: 10.1677/ERC-09-0129. Epub 2009 Sep 2.

PMID:
19726538
19.

Suppression of autoimmune diabetes by soluble galectin-1.

Perone MJ, Bertera S, Shufesky WJ, Divito SJ, Montecalvo A, Mathers AR, Larregina AT, Pang M, Seth N, Wucherpfennig KW, Trucco M, Baum LG, Morelli AE.

J Immunol. 2009 Mar 1;182(5):2641-53. doi: 10.4049/jimmunol.0800839.

20.

Molecular transduction mechanisms of cytokine-hormone interactions: role of gp130 cytokines.

Gerez J, Bonfiglio J, Sosa S, Giacomini D, Acuña M, Nagashima AC, Perone MJ, Silberstein S, Renner U, Stalla GK, Arzt E.

Exp Physiol. 2007 Sep;92(5):801-6. Review.

21.

Glucocorticoids in the regulation of transcription factors that control cytokine synthesis.

Liberman AC, Druker J, Perone MJ, Arzt E.

Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):45-56. Epub 2007 Mar 2. Review.

PMID:
17336577
22.

Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice.

Perone MJ, Bertera S, Tawadrous ZS, Shufesky WJ, Piganelli JD, Baum LG, Trucco M, Morelli AE.

J Immunol. 2006 Oct 15;177(8):5278-89.

23.

Transgenic galectin-1 induces maturation of dendritic cells that elicit contrasting responses in naive and activated T cells.

Perone MJ, Larregina AT, Shufesky WJ, Papworth GD, Sullivan ML, Zahorchak AF, Stolz DB, Baum LG, Watkins SC, Thomson AW, Morelli AE.

J Immunol. 2006 Jun 15;176(12):7207-20.

24.

Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cells.

Wang Z, Larregina AT, Shufesky WJ, Perone MJ, Montecalvo A, Zahorchak AF, Thomson AW, Morelli AE.

Am J Transplant. 2006 Jun;6(6):1297-311.

25.

Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries.

Southgate TD, Windeatt S, Smith-Arica J, Gerdes CA, Perone MJ, Morris I, Davis JR, Klatzmann D, Löwenstein PR, Castro MG.

Endocrinology. 2000 Sep;141(9):3493-505.

PMID:
10965923
26.

Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas.

Windeatt S, Southgate TD, Dewey RA, Bolognani F, Perone MJ, Larregina AT, Maleniak TC, Morris ID, Goya RG, Klatzmann D, Löwenstein PR, Castro MG.

J Clin Endocrinol Metab. 2000 Mar;85(3):1296-305.

PMID:
10720079
27.

Gender-dependent characteristics of the hypothalamo-corticotrope axis function in glucocorticoid-replete and glucocorticoid-depleted rats.

Chisari AN, Perone MJ, Giovambattista A, Spinedi E.

J Endocrinol Invest. 1998 Dec;21(11):737-43.

PMID:
9972672
28.

Direct regulation of GnRH transcription by CRF-like peptides in an immortalized neuronal cell line.

Tellam DJ, Perone MJ, Dunn IC, Radovick S, Brennand J, Rivier JE, Castro MG, Lovejoy DA.

Neuroreport. 1998 Oct 5;9(14):3135-40.

PMID:
9831440
29.

Procorticotrophin-releasing hormone: endoproteolytic processing and differential release of its derived peptides within AtT20 cells.

Perone MJ, Murray CA, Brown OA, Gibson S, White A, Linton EA, Perkins AV, Lowenstein PR, Castro MG.

Mol Cell Endocrinol. 1998 Jul 25;142(1-2):191-202.

PMID:
9783915
30.

Intracellular retention of the corticotrophin-releasing hormone (CRH) precursor within COS-7 cells.

Perone MJ, Windeatt S, Morrison E, Shering A, Tomasec P, Linton E, Lowenstein PR, Castro MG.

J Histochem Cytochem. 1998 Oct;46(10):1193-7.

PMID:
9742076
31.

Effect of the corticotrophin releasing hormone precursor on interleukin-6 release by human mononuclear cells.

Salas MA, Brown OA, Perone MJ, Castro MG, Goya RG.

Clin Immunol Immunopathol. 1997 Oct;85(1):35-9.

PMID:
9325067
32.

Prohormone and proneuropeptide synthesis and secretion.

Perone MJ, Castro MG.

Histol Histopathol. 1997 Oct;12(4):1179-88. Review.

PMID:
9302577
33.

Intracellular trafficking of prohormones and proneuropeptides: cell type-specific sorting and targeting.

Perone MJ, Windeatt S, Castro MG.

Exp Physiol. 1997 Jul;82(4):609-28. Review. No abstract available.

34.
35.

Procorticotrophin releasing hormone is endoproteolytically processed by the prohormone convertase PC2 but not by PC1 within stably transfected CHO-K1 cells.

Perone MJ, Ahmed I, Linton EA, Castro MG.

Biochem Soc Trans. 1996 Aug;24(3):497S. No abstract available.

PMID:
8879041
36.

Corticotrophin-releasing hormone receptor type 1: generation and characterization of polyclonal antipeptide antibodies and their localization in pituitary cells and cortical neurones in vitro.

Castro MG, Morrison E, Perone MJ, Brown OA, Murray CA, Ahmed I, Perkins AV, Europe-Finner G, Lowenstein PR, Linton EA.

J Neuroendocrinol. 1996 Jul;8(7):521-31.

PMID:
8843021

Supplemental Content

Loading ...
Support Center